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Abstract
Tigecycline (TGC) has demonstrated clinical efﬁcacy and safety, in comparison with imipenem/cilastatin in phase 3 clinical trials, for com-
plicated intra-abdominal infection (cIAI). The present study comprised a multicentre, open-label, randomized study of TGC vs. ceftriax-
one plus metronidazole (CTX/MET) for the treatment of patients with cIAI. Eligible subjects were randomized (1:1) to receive either an
initial dose of TGC (100 mg) followed by 50 mg every 12 h or CTX (2 g once daily) plus MET (1–2 g daily), for 4–14 days. The primary
endpoint was the clinical response in the clinically evaluable (CE) population at the test of cure (TOC) assessment. Of 473 randomized
subjects, 376 were CE. Among these, clinical cure rates were 70.4% (133/189) with TGC vs. 74.3% (139/187) with CTX/MET (95% CI
)13.1 to 5.1; p 0.009 for non-inferiority). Clinical cure rates for subjects with Acute Physiological and Chronic Health Evaluation II
scores ‡10 were 56.8% (21/37) with TGC vs. 58.3% (21/36) with CTX/MET. The microbiologic response was similar between the two
treatment arms, with microbiological eradication at TOC achieved in 68.1% (94/138) of TGC-treated subjects and 71.5% (98/137) of
CTX/MET-treated subjects. ( The most frequently reported adverse events (AEs) for both treatment arms were nausea (TGC, 38.6%
vs CTX/MET, 27.7%) and vomiting (TGC, 23.3% vs CTX/MET, 17.7%). Overall discontinuation rates as a result of an AE were 8.9% and
4.8% in TGC- and comparator-treated subjects, respectively. The results obtaned in the present study demonstrate that TGC mono-
therapy is non-inferior to a combination regimen of CTX/MET with respect to treating subjects with cIAI.
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Introduction
Tigecycline (TGC) is an expanded broad-spectrum antibiotic
with in vitro activity against bacterial pathogens associated
with intra-abdominal infections [1–4]. TGC has been demon-
strated to be non-inferior to imipenem/cilastin in two previ-
ous phase 3 efﬁcacy and safety trials for treatment of
complicated intra-abdominal infection (cIAI) [5,6]. The pres-
ent study was designed to compare the efﬁcacy and safety of
TGC with a commonly used combination of antibiotics,
ceftriaxone sodium plus metronidazole (CTX/MET), for
treatment of hospitalized patients with cIAI.
Materials and Methods
Design
The present trial was a phase 3b/4, multicentre, open-label,
prospective, randomized, comparative trial of hospitalized
adult subjects with a known or suspected diagnosis of cIAI.
The study was conducted in 53 centres in the USA, Canada
and Latin America. The two treatment arms of the study were
intravenous (IV) TGC (initial 100 mg dose infused over a 30-
min period, followed by 50 mg IV every 12 h) or IV CTX (2 g
once daily) plus MET (1–2 g daily, given in divided doses).
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The primary objective was to demonstrate the safety and
noninferiority of the clinical efﬁcacy of TGC vs. CTX/MET.
The primary endpoint was the clinical response in the clini-
cally evaluable (CE) population at the test of cure (TOC)
assessment.
The secondary objectives were: (i) to compare the micro-
biological efﬁcacy of TGC vs. that of CTX/MET and (ii) to
evaluate in vitro susceptibility data on TGC for the range of
bacteria that cause cIAI.
Institutional review board/ethics committee approval was
obtained for each study site. Written informed consent was
obtained from each subject or legal guardian prior to partici-
pation in the study. Eligible subjects were known or suspected
to have a cIAI with fever and/or leucocytosis, leucopaenia, or
left shift on cell differential count (>10% immature band
forms). Subjects had to have undergone a laparotomy, lapa-
roscopy or percutaneous drainage for an IAI within one calen-
dar day prior to, or after, the ﬁrst dose of study drug.
Subjects were excluded if they received more than1 day
of antibiotic therapy prior to enrollment.
The study drug was administered for a minimum of 4 days
and a maximum of 14 days. Subjects returned for TOC
assessment 10–21 days after the last dose of study drug, and
a clinical response of cure or failure, or an indeterminate
response, was determined by the investigator. Clinical
response was deﬁned as: cure (the study drug and initial inter-
vention resolved the IAI); failure [additional surgical or radio-
logical intervention and/or additional antibiotic treatment
were necessary to cure the infection, death after day 2 as a
result of the infection or a treatment-related adverse event
(AE) or discontinuation of study drug due to a treatment-
related AE]; or indeterminate (lost to follow-up; death within
2 days of ﬁrst dose of test compound or death after 2 days of
test compound because of reasons unrelated to infection).
Randomization
Subjects were stratiﬁed at randomization to two groups on
the basis of their Acute Physiological and Chronic Health
Evaluation (APACHE) II score: £10 or >10. Each group was
randomly assigned in a 1:1 ratio to receive either TGC or
CTX/MET, according to a central computerized randomiza-
tion/enrollment system generated by Wyeth Pharmaceuticals.
Bacterial isolates
Baseline aerobic and anaerobic cultures were obtained from
the primary intra-abdominal site of infection during the quali-
fying surgical procedure. Two sets of blood culture were
obtained prior to administration of the ﬁrst dose of study
drug. All recovered isolates were identiﬁed and tested at a
central laboratory (Covance Central Laboratory Services,
Inc., Indianapolis, IN, USA) by a standard procedure
approved by the CLSI Subcommittee on Antimicrobial Sus-
ceptibility Testing. For TGC, Food and Drug Administration
approved breakpoints were used.
Analysis populations
Several populations were deﬁned for analysis. Subjects who
provided written informed consent and were randomized
were included in the intent-to-treat (ITT) population. Sub-
jects who received at least one dose of study drug formed
the modiﬁed intent-to-treat (mITT) or safety population.
Subjects in the mITT population who met minimal disease
criteria of a cIAI were included in the clinical modiﬁed intent-
to-treat (c-mITT) population. From the c-mITT population,
the primary efﬁcacy population, the CE population was
deﬁned as subjects who met all inclusion and exclusion crite-
ria, received therapy for at least 4 days in case of clinical cure
or at least 2 days in case of clinical failure, received no poten-
tially effective concomitant antibacterial therapy after the ﬁrst
dose of study drug through the TOC assessment, and had a
TOC visit 8–44 days after the last dose of study drug. The
microbiologically positive mITT population (m-mITT) met the
minimal disease criteria and had a conﬁrmed baseline isolate.
The microbiologically evaluable (ME) population was
deﬁned as subjects who were CE and also had a baseline
isolate susceptible to both TGC and comparator.
Statistical analysis
Statistical analysis was performed by the Clinical Biostatistics
Department Quintiles (Bloemfontein, South Africa). Assum-
ing an eligibility rate of at least 70%, approximately 430 sub-
jects were to be enrolled to obtain 301 clinically eligible
subjects. Assuming that the two treatment groups were
equally effective, with favourable clinical response rates (i.e.
cure) of 80% at the TOC assessment, 151 subjects per treat-
ment group were required to ensure with 90% probability
(i.e. 90% power) that the lower limit of a two-sided 95% CI
for the true difference (tigecycline minus the comparator) in
efﬁcacy was >)15%.
The primary end point was the clinical response at the
TOC visit for the CE population. Primary analysis was
applied to the CE population with a comparison of the clini-
cal success rate (cure vs. failure) between treatment groups.
Non-inferiority (NI) was concluded if the lower limit of the
two-sided 95% conﬁdence interval (corrected for continuity)
was >)15. Supplementary analyses were performed for the
mITT, c-mITT, m-mITT, ME, and CE populations. An interim
analysis was not planned for the present study.
Analysis of safety data included a comparison of the pro-
portions of subjects experiencing AEs, and potentially clini-
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cally important laboratory and vital sign values. Chi-square
or Fisher’s exact test were used to compare proportions
(e.g. efﬁcacy response, AEs). Analysis of variance and
Kaplan–Meier methods were employed to assess treatment
group differences in length of hospital stay, time to deferves-
cence and duration of IV antibiotic treatment.
Results
Subject disposition and analysis populations
Between September 2005 and February 2008, 473 subjects
were enrolled in the study at 53 sites in six countries in
North and South America. After elimination of six subjects
from the study prior to receiving study drug (Fig. 1), 467
subjects constituted the mITT or safety population (TGC,
n = 236; CTX/MET, n = 231), with 448 subjects exhibiting
clinical evidence of a cIAI (c-mITT). Within this latter cohort,
376 subjects were CE (TGC, n = 189; CTX/MET, n = 187)
and, from 321 subjects, a baseline isolate was recovered
from an intra-abdominal or blood source, comprising the m-
mITT population. A total of 275 subjects (TGC, n = 138;
CTX/MET, n = 137) met clinical evaluability criteria and had
a baseline isolate recovered from an intra-abdominal source
or blood source that was susceptible to the study drugs (ME
population). Forty-eight TGC and 49 CTX/MET subjects
were excluded from the CE population; primary reasons
were ‘no clinical evaluation at the TOC assessment’ (TGC,
n = 15; CTX/MET, n = 10) and ‘use of prohibited/concomi-
tant antibiotics’ (TGC, n = 11; CTX/MET, n = 12). Rates and
reasons for exclusion were generally similar between treat-
ment groups.
Demographic and baseline medical characteristics
Demographic characteristics of the mITT population were
similar between the two treatment groups (Table S1). Most
subjects were males (64.7%) and Caucasian (65.3%). The
mean age was 48 years. There were no signiﬁcant differences
TGC 
Safty population Safty population
N = 236
TGC 
Clinical mITT
(c-mITT)
N = 228
Subjects who didn’t 
meet evaluability
N = 39
Subjects with no
baseline isolate
Subjects with no
baseline isolate
Subjects with no
baseline isolate
N = 65
TGC 
Clinically Evaluable
(CE)
N = 189
        and
susceptibilities
N = 51
TGC
Microbiologically Microbiologically
Evaluable (ME) Evaluable (ME)
N = 138
TGC 
Microbiological
        mITT 
(m-mITT)
N = 163
Subjects without
minimal disease
criteria
N = 8
CTX/MET 
N = 231
CTX/MET 
Clinical mITT
(c-mITT)
N = 220
Subjects who didn’t 
meet evaluability
N = 33 N = 62
CTX/MET 
Clinically
Evaluable
(CE)
N = 187
Subjects with no
baseline isolate
and
susceptibilities
N = 50
CTX/MET
N = 137
CTX/MET
Microbiological
       mITT(m-mITT)
N = 158
minimal disease
criteria
Subjects without 
N = 11
Intent-to-Treat
(ITT)
N = 473
Did not receive 
Study drug
N = 6
(1 TGC;  5 CTX/MET)
Modified ITT mITT Modified ITT mITT
FIG. 1. Study ﬂow diagram. c-mITT,
Clinical modiﬁed intent-to-treat; CTX/
MET, ceftriaxone plus metronidazole;
ITT, intent-to-treat; mITT, modiﬁed
intent-to-treat; TGC, tigecycline.
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between the treatment groups in the number or types of
baseline infections. The most common diagnosis was compli-
cated appendicitis (52%), followed by complicated diverticuli-
tis (12%), purulent peritonitis (11%) and intra-abdominal
abscess (11%) (Table 1).
A proportion of subjects received at least 72 h of antibi-
otic therapy before enrollment and were enrolled in the
study as prior antibiotic failures (10.6% TGC, 4.3% CTX/
MET, p 0.010). A total of 335 (72%) subjects in the mITT
population had peritonitis at the time of qualifying surgical
procedure. Abscesses were present in 270 (59%) subjects:
49% of these subjects had a single abscess, whereas 10% had
multiple abscesses. After completion of the qualifying surgical
procedure or percutaneous drainage, 213 (90%) subjects in
the TGC arm and 209 (91%) subjects in the CTX/MET arm
had minimal or no residual contamination.
Clinical efﬁcacy
In the CE population, clinical cure was reported for 133 of 189
(70%) of the TGC-treated subjects and 139 of 187 (74%) of
the comparator arm ()4.0; 95% CI )13.1 to 5.1; p 0.009 for
NI) (Table 1). Clinical cure rates for the ME population were
66% and 70% ()3.4; 95% CI )14.5 to 7.8; p 0.020 for NI),
respectively (Tables 2 and 3). In the c-mITT population, clinical
cure was reported for 145 of 228 (64%) of the TGC-treated
subjects and 155 of 220 (71%) of CTX/MET-treated subjects
()7.0; 95% CI )15.8 to 1.08; p 0.038 for NI).
There were no signiﬁcant differences in clinical response
between treatment groups based on primary diagnosis or
APACHE II score (Table 1). For complicated appendicitis,
clinical cure at TOC was similar between TGC and CTX/
MET [74% vs. 77%, respectively ()3.9; 95% CI )17.0 to 9.3)]
and complicated diverticulitis [65% vs. 72%, respectively
()7.0; 95% CI )38.8 to 24.8)]. Subjects with intra-abdominal
abscess(es) had lower cure rates [52% vs. 47%, respectively
(5.0; 95% CI )31.0 to 41.0)]. Seventeen subjects in the ME
population had concomitant bacteraemia. In this subpopula-
tion, TGC was associated with clinical cure rates of seven of
eight (88%) and CTX/MET with six of nine (67%) subjects,
respectively. There were no signiﬁcant differences between
groups in terms of cure rates or eradication.
Microbiologic efﬁcacy
Escherichia coli followed by members of the Bacteroides fragilis
group were the most commonly isolated bacteria. For the
ME population, clinical cure rates for the different pathogens
were similar between the two treatment groups (Table 2).
At TOC in the ME population, infections were cured in
TABLE 1. Cure rate at test of cure
by primary diagnosis and Acute
Physiological and Chronic Health
Evaluation (APACHE) II score
(clinically evaluable population)
Diagnosis TGC, n/N (%)
CTX/MET,
n/N (%)
Difference
TGC – CTX/MET
(95% CI)b
Complicated appendicitis 72/98 (73.5) 75/97 (77.3) )3.9 ()17.0, 9.3)
Purulent peritonitis 17/23 (73.9) 16/18 (88.9) )15.0 ()43.0, 13.1)
Intra-abdominal abscessa 11/21 (52.4) 9/19 (47.4) 5.0 ()31.0, 41.0)
Complicated diverticulitis 13/20 (65.0) 18/25 (72.0) )7.0 ()38.8, 24.8)
Perforation of the intestine 9/14 (64.3) 13/17 (76.5) )12.2 ()50.9, 26.5)
Gastric/duodenal perforation 8/9 (88.9) 7/7 (100.0) )11.1 ()44.3, 22.1)
Complicated cholecystitis 3/4 (75.0) 1/4 (25.0) 50.0 ()35.0, 100.0)
Overall adjusted differencec )6.3 ()15.3, 2.7)
APACHE II score
<10 112/152 (73.7) 118/151 (78.1) )4.5 ()14.7, 5.8)
10–15 17/30 (56.7) 16/28 (57.1) )0.5 ()29.4, 28.5)
>15 4/7 (57.1) 5/8 (62.5) )5.4 ()68.4, 57.7)
Overalld 133/189 (70.4) 139/187 (74.3) )4.0 ()13.1, 5.1)e
aAs deﬁned by the investigator.
bCalculated using asymptotic method corrected for continuity.
cAdjusted difference and 95% CI calculated using a generalized linear model with binomial probability function and
identity link.
dEstimates of the difference, CI and hypothesis tests are weighted by using minimum risk weights (method of Mehro-
tra and Railkar).
eTest for non-inferiority, p 0.009.
TGC, Tigecycline; CTX/MET, ceftriaxone plus metronidazole.
TABLE 2. Clinical cure rates at test of cure by pathogen
[microbiologically evaluable (ME) population]
TGC ME,
n/N (%)
CTX/Met ME,
n/N (%)
Escherichia coli 67/96 (69.8) 61/92 (66.3)
Klebsiella spp. 6/15 (40.0) 13/19 (68.4)
Pseudomonas aeruginosa 14/20 (70.0) 7/12 (58.3)
Bacteroides fragilis groupa 51/80 (63.8) 53/81 (65.4)
Clostridium spp. 16/19 (84.2) 10/12 (83.3)
Peptostreptococcus spp. 6/10 (60.0) 8/10 (80.0)
Enterococcus spp. 20/29 (69.0) 8/19 (42.1)
Staphylococcus aureus 2/3 (66.7) 2/3 (66.7)
Streptococcus anginosus 15/19 (78.9) 14/20 (70.0)
aB. fragilis group = B. fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacte-
roides vulgatus, Parabacteroides distasonis.
TGC, Tigecycline; CTX/MET, ceftriaxone plus metronidazole.
CMI Towﬁgh et al. Clinical trial of tigecycline for intra-abdominal infections 1277
ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI
No claim to original US government works, 16, 1274–1281
68.0% and 67.0% of all monomicrobial and polymicrobial infec-
tions, respectively, in the TGC-treated subjects, and 71.5%
and 68.3% of all monomicrobial and polymicrobial infections,
respectively, in the CTX/MET-treated subjects. In vitro activity
against selected baseline isolates is shown in Table 3.
Adverse events
Safety and tolerability of TGC, including the frequency and
distribution of AEs, were similar to those of CTX/MET. One
hundred subjects reported one or more serious adverse
events (SAEs) during the study (TGC, n = 51; CTX/MET,
n = 49). There were no statistically signiﬁcant differences
between treatment groups in the overall incidence of sub-
jects reporting one or more SAEs (p 1.000) or in the inci-
dences of any reported SAE term or body system. The most
frequently reported SAEs overall were abscess (31/467;
6.6%), infection (7/467; 1.5%), respiratory failure (7/467;
1.5%), abdominal pain (6/467; 1.3%) and ileus (6/467; 1.3%).
Treatment emergent adverse events (TEAEs) in the TGC
treatment arm (195/236; 82.6%) did not differ signiﬁcantly
from the CTX/MET treatment arm (189/231; 81.8%) (p
0.904) (Table 4). The most frequently reported TEAE in
either treatment group was nausea, reported in 91 of 236
(38.6%) TGC-treated subjects and 64 of 231 (27.7%) CTX/
MET-treated subjects. Vomiting was the second most fre-
quently reported TEAE, reported in 55 of 236 (23.3%) TGC-
treated subjects and 41 of 231 (17.7%) CTX/MET-treated
subjects. Signiﬁcantly more subjects treated with TGC
reported (or were diagnosed with) the TEAEs of nausea,
oral moniliasis, leukocytosis and deep venous thrombosis.
Signiﬁcantly more subjects treated with CTX/MET reported
the TEAEs of generalized oedema, atelectasis and taste per-
version. Of the 26 subjects reporting AEs of infection, Clostri-
dum difﬁcile was reported in only one CTX/MET subject.
Twenty-one of 236 (8.9%) TGC-treated and 11 of 231
(4.8%) CTX/MET-treated subjects discontinued study drug
because of an AE (p 0.099). There were no signiﬁcant differ-
ences between treatment groups in frequency of any single
AE leading to the discontinuation of study drug. The most
frequently reported AE leading to discontinuation of study
drug were nausea in seven of 467 subjects (1.5%) and
abscess in seven of 467 subjects (1.5%).
TABLE 3. MIC ranges and MIC50 and MIC90 values for selected primary baseline isolates (microbiologically evaluable popula-
tion)
Baseline isolate (n)
Tigecycline (mg/L) Ceftriaxone (mg/L) Metronidazole (mg/L)
Minimum Maximum MIC50 MIC90 Minimum Maximum MIC50 MIC90 Minimum Maximum MIC50 MIC90
Bacteroides fragilis (53) 0.25 32.0 1.0 4.0 16.00 256.00 32.0 128.0 0.12 4.00 1.0 2.0
Clostridium perfringes (8) 0.12 4.00 NA NA 0.06 4.00 NA NA 0.50 16.00 NA NA
Enterococcus faecalis (19) 0.03 0.25 0.06 0.12 8.00 64.00 64.0 64.0
Escherichia coli (188) 0.06 1.00 0.12 0.25 0.03 16.00 0.06 0.12
Klebsiella pneumoniae (29) 0.25 0.50 0.25 0.50 0.03 0.12 0.06 0.12
Staphylococcus aureus (6) 0.06 0.25 NA NA 2.00 64.00 NA NA
Streptococcus anginosus (39) 0.03 0.12 0.03 0.03 0.06 0.50 0.25 0.50
NA, Not available for isolates from a population of <10 subjects.
TABLE 4. Treatment-emergent adverse eventsa proﬁle
(modiﬁed intent-to-treat)
Adverse event
TGC,
N = 236,
n (%)
CTX/Met,
N = 231,
n (%) pb
Overall 195 (82.6) 189 (81.8)
Nausea 91 (38.6) 64 (27.7) 0.014
Vomiting 55 (23.3) 41 (17.7)
Diarrhoea 42 (17.8) 40 (17.3)
Abscess 23 (9.7) 15 (6.5)
Abdominal pain 22 (9.3) 16 (6.9)
Leucocytosis 19 (8.1) 4 (1.7) 0.002
Local reaction to
procedure
18 (7.6) 14 (6.1)
Fever 17 (7.2) 18 (7.8)
Infection 17 (7.2) 9 (3.9)
Anaemia 16 (6.8) 8 (3.5)
Hypokalaemia 16 (6.8) 21 (9.1)
Headache 14 (5.9) 22 (9.5)
Insomnia 23 (9.7) 24 (10.4)
Constipation 14 (5.9) 14 (6.1)
Thrombocythaemia 13 (5.5) 15 (6.5)
Pruritis 13 (5.5) 12 (5.2)
Hypoproteinaemia 11 (4.7) 4 (1.7)
Abnormal healing 9 (3.8) 8 (3.5)
Hyperglycaemia 9 (3.8) 8 (3.5)
Hypertension 9 (3.8) 11 (4.8)
Peripheral oedema 9 (3.8) 7 (3.0)
Pharyngitis 9 (3.8) 8 (3.5)
Ileus 8 (3.4) 16 (6.9)
Deep venous thrombosis 8 (3.4) 1 (0.4) 0.037
Oral moniliasis 8 (3.4) 1 (0.4) 0.037
Anxiety 7 (3.0) 12 (5.2)
Pulmonary physical ﬁnding 7 (3.0) 6 (2.6)
Respiratory failure 6 (2.5) 10 (4.3)
Abdominal distention 5 (2.1) 11 (4.8)
Dyspnea 5 (2.1) 7 (3.0)
Pleural effusions 4 (1.7) 7 (3.0)
Rash 4 (1.7) 7 (3.0)
Taste perversion 2 (0.8) 9 (3.9) 0.035
Generalized oedema 1 (0.4) 7 (3.0) 0.036
Atelectasis 0 (0.0) 7 (3.0) 0.007
aA treatment-emergent adverse event is deﬁned as any adverse event that was
present from the day of ﬁrst administration of study drug until 15 days after the
last administration of study drug.
bAdverse event is reported if incidence is ‡3.0% or p <0.05.
TGC, Tigecycline; CTX/MET, ceftriaxone plus metronidazole.
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Seven subjects in the mITT population died during the
study: four of 236 TGC-treated and three of 231 CTX/MET-
treated subjects. There were no deaths in subjects who
were randomized but received no study drug. SAEs with an
outcome of death in TGC-treated subjects included aspira-
tion pneumonia, cerebrovascular accident, gastrointestinal
carcinoma, septic shock, and cardiac arrest. SAEs with an
outcome of death in CTX/MET-treated subjects included
congestive heart failure, coronary heart disorder, respiratory
failure and retroperitoneal haemorrhage. None of the deaths
were considered to be related to study drug.
Discussion
cIAIs often present with peritonitis and may involve intra-
abdominal abscess [7]. They develop from a primary source
in the gastrointestinal tract and are associated with signiﬁ-
cant morbidity and mortality. Intra-abdominal infections are
associated with an overall mortality rate of approximately
6%, with age, the source of infection and burden of co-
morbidities affecting outcome [8]. Management involves
ﬂuid resuscitation, source control and appropriate antimi-
crobial therapy.
Inadequate antimicrobial treatment is independently asso-
ciated with outcome [9,10]. The choice of empiric antibiotic
therapy is complicated in the case of bacterial resistance [11]
and the increasing numbers of extended-spectrum b-lactam-
ase-producing Gram-negative bacteria, including CTX-M-type
producing E. coli and multidrug-resistant strains of B. fragilis,
which may be more prevalent among high-risk, hospitalized
patients [11–13]. The authors of current guidelines have not
concluded that one antibacterial regimen is superior to the
other but emphasize the importance of broad-spectrum
agents covering resistant pathogens [7,12].
The present study evaluated the safety and efﬁcacy of tige-
cycline in treating hospitalized subjects with cIAI vs. an anti-
biotic regimen different from that used in the tigecycline
registration trials. TGC met the statistical criteria for non-
inferiority to CTX/MET in the primary analysis with a clinical
cure rate of 70% vs. 74% in the comparator population. The
study design did not require a speciﬁc distribution of cIAI
diagnosis or restrict the number of subjects with an
APACHE score <10. As such, 51.6% of subjects had a diag-
nosis of complicated appendicitis and 78.5% of subjects had
an APACHE II score <10. Although it is encouraging that
TGC cure rates were similar to those obtained with CTX/
MET across all cIAI diagnoses and in subjects with an
APACHE II score >10, the sample size is small and additional
studies are required in more severely ill populations.
At the microbiological level, efﬁcacy comparisons con-
ﬁrmed the results of the primary analysis. In the ME popula-
tion, the clinical cure rates for those infected with the most
common pathogens (i.e. E. coli and B. fragilis group members
were 69.8% vs. 66.3%, and 63.8% vs. 65.4% when treated
withTGC and CTX/MET, respectively).
There were no signiﬁcant differences overall between the
two treatment arms with respect to SAEs or TEAEs.
TGC-treated subjects were signiﬁcantly more likely to have
nausea, oral moniliasis, leukocytosis and deep venous throm-
bosis. CTX/MET subjects were signiﬁcantly more likely to
have generalized oedema, atelectasis and taste perversion.
The results obtained in the present study are consistent
with the ﬁndings of previous phase 3 trials and conﬁrm that
TGC has good activity against the pathogens associated with
cIAI and is an effective and well-tolerated monotherapy
option for the treatment of adult patients with cIAI [5,6,13].
In areas where multidrug-resistant pathogens are being
reported, tigecycline may offer an alternative to the combi-
nation of a cephalosporin plus metronidazole, particularly
where extended-spectrum b-lactamase-producing organisms
have reached high levels. Further data are needed to justify
the use of empiric TGC monotherapy.
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